The World health Organization says nearly 35 million people world over are living with HIV/AIDS. What has caused a stir in community of medics is the new achievement taking one step closer to cure HIV.

The European Research Council said the virus is known to be the ultimate evolver because of being able to evolve so quickly to repel drugs and immune defenses.

Researchers have always been challenged by the virus, which is capable of evading detection from the immune system and mutating rapidly into new strains. But now, they have devised a formula for a vaccine that can stimulate the body to produce antibodies which bind to the HIV virus and ultimately keep the infection from taking place.

The National Institute of Allergy and Infectious Diseases has funded the three studies. Dennis Burton, chair of The Scripps Research Institute Department of Immunology and Microbial Science, said the results hold great promise for a drug that can finally treat patients with HIV/AIDS.

"The immunogen proved capable of launching the mouse immune systems in the right direction. We look forward to the prospect of testing this exciting strategy in humans", said William Schief, Ph.D. Professor Department of Immunology and Microbial Science California Campus.

The long-term goal of the researchers is to develop a vaccine that encourages the body to produce antibodies that bind to HIV and ensure prevention of infection by many if not all of the virus' variants.

The vaccine has worked well of the virus' variants to trigger the antibody response.